AZD6094

Phase 2Small molecule

AstraZeneca

AZD6094 is one of 56 small molecule programs targeting Gastric Adenocarcinoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Gastric AdenocarcinomaActive, not recruiting

Papillary Renal Cell CarcinomaActive, not recruiting

Gastric AdenocarcinomaPhase 1/Phase 2

Active, not recruiting

Papillary Renal Cell CarcinomaPhase 2

Active, not recruiting

Competition

Competitive Landscape

150 competitors in Gastric Adenocarcinoma

#DrugCompanyPhaseTrials

Taxol

Teva

Phase 3

13 2

Eloxatin

Teva

Phase 3

12 3

Keytruda

Merck & Co.

Phase 3

3 4

Opdivo

Bristol-Myers Squibb

Phase 3

2 5

Camptosar

Pfizer

Phase 3

1 6

Elunate

Takeda

Phase 3

1 7

Xeloda

EEngelhard Arzneimittel GmbH & Co.KG

Phase 3

6 8

Taxotere

AAvyxa

Phase 3

6 9

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

4 10

Adrucil

EElorac, Inc.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Gastric Adenocarcinoma2 trials

Phase Ib, Single-arm Study of AZD6094 (Volitinib) in Combination With Docetaxel, in Any Solid Cancer and Sequential Phase II, Single-arm Study of AZD6094 (Volitinib) in Combination With Docetaxel in Advanced Gastric Adenocarcinoma Patients With MET Amplification as a Second Line Treatment

Completed·SSamsung Medical Center·Phase 1/2·NCT02447406·7 enrolled

Study of AZD6094 (Volitinib) in Combination With Docetaxel, in Advanced Gastric Adenocarcinoma Patients With MET Overexpression as a Second-line Treatment

Completed·SSamsung Medical Center·Phase 2·NCT02447380·2 enrolled

Papillary Renal Cell Carcinoma1 trial

A Phase II Trial to Evaluate the Efficacy of AZD6094 (HMPL-504) in Patients With Papillary Renal Cell Carcinoma (PRCC)

Completed· AstraZeneca logo

AstraZeneca·Phase 2·NCT02127710·111 enrolled

DME1 trial

Absolute Bioavailability and ADME Study of Savolitinib in Healthy Male Subjects

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT04675021·8 enrolled

Cardiac Repolarization1 trial

A Study to Investigate the Effect of Single Dose of AZD6094 (600 mg) on Cardiac Repolarization in Healthy Volunteers

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT03258515·45 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for AZD6094. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — AZD6094 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for AZD6094. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AstraZeneca company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: AstraZeneca

AZD6094

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Gastric Adenocarcinoma2 trials

Papillary Renal Cell Carcinoma1 trial

DME1 trial

Cardiac Repolarization1 trial

References

Drug Info

Quick Facts

Related News